On April 28, 2022 Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that management will participate in one-on-one meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day (Press release, Tvardi Therapeutics, APR 28, 2022, View Source [SID1234613141]). The conference is being held in a virtual format on Tuesday, May 3rd, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!